Alector LLC Company Profile

04:20 EST 18th January 2019 | BioPortfolio

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams. For more information, contact

News Articles [35 Associated News Articles listed on BioPortfolio]

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Alector, a biotech company focusing on the immune system to treat degenerative brain disorders such as Alzheimer’s disease, has filed to go public to fund human tests of its experimental therapies. ...

Poseida, Alector readying IPOs

An initial public offering has been filed by neurodegenerative disorders company Alector seeking to raise up to $150 million. -More- 

Alector raises $133m to advance Alzheimer’s disease drugs

Biotechnology firm Alector has raised $133m in a series E financing round to support further development of its clinical programmes...Read More... The post Alector raises $133m to advance Alzheimer’...

Alector starts Phase l trial of AL001 for frontotemporal dementia

Alector has commenced a Phase l INFRONT trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 for the...Read More... The post Alector starts Phase l trial of A...

Biotech startup Alector raises $133M

Alector, a biotech startup working on treatments for neurodegenerative disorders, including Alzheimer's, raised $133 million  -More- 

Alector starts Phase I study of AL002 for Alzheimer’s disease

Alector has started a Phase I INVOKE clinical study to evaluate AL002 for the treatment of Alzheimer’s disease. The trial...Read More... The post Alector starts Phase I study of AL002 for Alzheimer...

Alector Closes $133 Million to Expand Alzheimer’s Programs

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

Alector Snags $133M to Activate Immune Cells Against Neurodegeneration

Pharmaceutical companies have been working for years to find a drug that could break up the toxic clusters of proteins associated with Alzheimer’s disease and other neurodegenerative disorders. Many...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Alector LLC

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, ...

Alector, Inc.

Alector is a privately owned biotechnology company whose mission is to develop therapies that harness the immune system to treat neurodegenerative diseases and cancer. Alector was...

More Information about "Alector LLC" on BioPortfolio

We have published hundreds of Alector LLC news stories on BioPortfolio along with dozens of Alector LLC Clinical Trials and PubMed Articles about Alector LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alector LLC Companies in our database. You can also find out about relevant Alector LLC Drugs and Medications on this site too.

Quick Search


Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record